

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2022

(Commission File No. 001-41157)

---

**BIONOMICS LIMITED**

(Translation of registrant's name into English)

---

200 Greenhill Road

Eastwood SA 5063

Tel: +618 8150 7400

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes  No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On May 16 2022, Bionomics Limited (the “Company”) announced on the Australian Securities Exchange (ASX) that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences. An audio webcast link for each event, when available, will be posted to Bionomics’ website in the Investors-Events and Presentations section. The details are furnished herewith as Exhibit 99.1 to this report on Form 6-K.

## EXHIBIT INDEX

Exhibit	Description
99.1	<a href="#">Bionomics Limited to Participate in Upcoming Investor Conferences</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**Bionomics Limited**  
(Registrant)

By: /s/ Errol De Souza  
Name: Errol De Souza, Ph.D.  
Title: Executive Chairman

Date: May 16, 2022



## **Bionomics Limited to Participate in Upcoming Investor Conferences**

May 16, 2022

ADELAIDE, Australia, May 16, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences:

- Citibank Biotech's Mood Disorders/Mental Health Panel
  - o Taking place virtually on May 18<sup>th</sup>, 2022 at 11:00 am ET
- Berenberg Capital Markets Emerging Biotech Conference
  - o Taking place virtually and in-person in San Francisco on May 19<sup>th</sup>, 2022
- H.C. Wainwright Global Investment Conference
  - o Taking place virtually and in-person in Miami Beach from May 23<sup>rd</sup> - 26<sup>th</sup>

An audio webcast link for each event, when available, will be posted to Bionomics' website in the Investors-Events and Presentations section.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

**General**

Ms Suzanne Irwin  
Company Secretary  
+61 8 8150 7400  
CoSec@bionomics.com.au

**Investor Relations**

Mr. Connor Bernstein  
Vice President, Strategy and Corporate  
Development  
+1 (650) 524-5143  
cbernstein@bionomics.com.au

**Investor Relations**

Kevin Gardner  
kgardner@lifesciadvisors.com

---

## **About Bionomics Limited**

Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the  $\alpha 7$  nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

[www.bionomics.com.au](http://www.bionomics.com.au)

---

---

